Neuropathology of parkinsonism in patients with pure alzheimer's disease

Journal of Alzheimer's Disease

Volumn 39, Issue 1, 2014, Pages 115-120

  Horvath, Judit ^a   Burkhard, Pierre R ^a   Herrmann, François R ^a   Bouras, Constantin ^a   Kövari, Enikö ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alzheimer's disease; histology; parkinsonism; pathology; putamen; substantia nigra

Indexed keywords

TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRADYKINESIA; CELL DENSITY; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GAIT DISORDER; HUMAN; HUMAN TISSUE; MALE; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RIGIDITY; SUBSTANTIA NIGRA PARS COMPACTA; TREMOR; VERY ELDERLY;

ALZHEIMER'S DISEASE; HISTOLOGY; PARKINSONISM; PATHOLOGY; PUTAMEN; SUBSTANTIA NIGRA;

AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; LEWY BODIES; MALE; NEUROFIBRILLARY TANGLES; NEURONS; PARKINSONIAN DISORDERS; PUTAMEN; SUBSTANTIA NIGRA;

EID: 84892683368     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131289     Document Type: Article

References (42)

1. Attems J, Quass M, Jellinger KA (2007) Tau and alphasynuclein brainstem pathology in Alzheimer disease: Relation with extrapyramidal signs. Acta Neuropathol 113, 53-62. (Pubitemid 44782929)
2. Molsa PK, Sako E, Paljarvi L, Rinne JO, Rinne UK (1987) Alzheimer's disease: Neuropathological correlates of cognitive and motor disorders. Acta Neurol Scand 75, 376-384. (Pubitemid 17117483)
3. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J (1989) Clinical and pathological aspects of parkinsonism in Alzheimer's disease.Arole for extranigral factors Arch Neurol 46, 651-657. (Pubitemid 19150944)
4. Portet F, Scarmeas N, Cosentino S, Helzner EP, SternY(2009) Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol 66, 1120-1126.
5. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, Dubois B, Sarazin M, Brandt J, Albert M, Marder K, Bell K, Honig LS, Wegesin D, Stern Y (2004) Motor signs during the course of Alzheimer disease. Neurology 63, 975-982. (Pubitemid 39287903)
6. Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, Bell K, Sano M, Devanand DP, Bylsma F, et al. (1994) Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: Prospective analyses from the Predictors Study. Neurology 44, 2300-2307.
7. Ditter SM,Mirra SS (1987) Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 37, 754-760. (Pubitemid 17064661)
8. Kazee AM, Cox C, Richfield EK (1995) Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 9, 61-67.
9. Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW (2005) The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 64, 1397-1403. (Pubitemid 40570508)
10. Stern Y, Jacobs D, Goldman J, Gomez-Tortosa E, Hyman BT, Liu Y, Troncoso J, Marder K, Tang MX, Brandt J, Albert M (2001) An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 58, 460-465. (Pubitemid 32217463)
11. Tyrrell PJ, RossorMN(1989) Extrapyramidal signs in dementia of Alzheimer type. Lancet 2, 920. (Pubitemid 19245312)
12. Gibb WR, Mountjoy CQ, Mann DM, Lees AJ (1989) The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry 52, 193-200. (Pubitemid 19054193)
13. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN (1995) Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 37, 300-312.
14. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: A meta-analysis. Neurobiol Aging 24, 1-23. (Pubitemid 35454140)
15. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE (1997) Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 41, 368-374. (Pubitemid 27114048)
16. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Markakis D (1984) Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett 52, 1-6. (Pubitemid 15179716)
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184.
18. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
19. Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV (2006) Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 60, 677-687. (Pubitemid 46048485)
20. Gold G, Bouras C, K̈ovari E, Canuto A, Glaria BG, Malky A, Hof PR, Michel JP, Giannakopoulos P (2000) Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol 99, 579-582; discussion 583-574. (Pubitemid 30201322)
21. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, K̈ovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 71, 362-381.
22. Mirra SS, Heyman A,McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
23. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary. Neurobiol Aging 18, S91-S94. (Pubitemid 27454705)
24. Parent A, Hazrati LN (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20, 91-127.
25. Durieux PF, Schiffmann SN, deKerchove d'ExaerdeA(2011) Targeting neuronal populations of the striatum. Front Neuroanat 5, 40.
26. Schmitz C, Hof PR (2005) Design-based stereology in neuroscience. Neuroscience 130, 813-831. (Pubitemid 40094616)
27. Van Otterloo E, O'Dwyer G, Stockmeier CA, Steffens DC, Krishnan RR, Rajkowska G (2009) Reductions in neuronal density in elderly depressed are region specific. Int J Geriatr Psychiatry 24, 856-864.
28. Rinne JO, Rummukainen J, Paljarvi L, Sako E,Molsa P, Rinne UK (1989) Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 317, 325-332.
29. Schneider JA, Li JL, Li Y, Wilson RS, Kordower JH, Bennett DA (2006) Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol 59, 166-173. (Pubitemid 43042883)
30. Colloby SJ, McParland S, O'Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 135, 2798-2808.
31. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114(Pt 5), 2283-2301.
32. RossGW, Petrovitch H, Abbott RD, Nelson J, MarkesberyW, Davis D, Hardman J, Launer L, Masaki K, Tanner CM,White LR (2004) Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 56, 532-539. (Pubitemid 39319343)
33. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121, 171-181.
34. Grinberg LT, Rub U, Ferretti RE, Nitrini R, Farfel JM, Polichiso L, Gierga K, Jacob-Filho W, Heinsen H (2009) The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset Neuropathol Appl Neurobiol 35, 406-416.
35. Attems J, Thal DR, Jellinger KA (2012) The relationship between subcortical tau pathology and Alzheimer's disease. Biochem Soc Trans 40, 711-715.
36. Attems J, Thomas A, JellingerK(2012) Correlations between cortical and subcortical tau pathology. Neuropathol Appl Neurobiol 38, 582-590.
37. Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA (2012) Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71, 258-266.
38. Louis ED, Bennett DA (2007) Mild Parkinsonian signs: An overview of an emerging concept. Mov Disord 22, 1681-1688. (Pubitemid 47597591)
39. Louis ED, Tang MX, Schupf N (2010) Mild parkinsonian signs are associated with increased risk of dementia in a prospective, population-based study of elders. Mov Disord 25, 172-178.
40. Richards M, Stern Y, Mayeux R (1993) Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 43, 2184-2188. (Pubitemid 23346944)
41. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA (2003) Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol 60, 539-544. (Pubitemid 36427968)
42. Zhou G, Duan L, Sun F, Yan B, Ren S (2010) Association between mild parkinsonian signs and mortality in an elderly male cohort in China. J Clin Neurosci 17, 173-176.